Astrazeneca PLC (AZN) Receives “Hold” Rating from Shore Capital
Astrazeneca PLC (NYSE:AZN)‘s stock had its “hold” rating reissued by stock analysts at Shore Capital in a report issued on Saturday.
A number of other analysts also recently issued reports on AZN. Leerink Swann reiterated a “hold” rating and issued a $34.00 price target on shares of Astrazeneca PLC in a report on Thursday, June 16th. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Saturday, June 25th. Deutsche Bank AG reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Monday, June 27th. Argus started coverage on shares of Astrazeneca PLC in a report on Tuesday, July 12th. They issued a “hold” rating on the stock. Finally, Bank of America Corp. reiterated a “buy” rating and issued a $36.65 price target on shares of Astrazeneca PLC in a report on Monday, July 18th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Astrazeneca PLC presently has an average rating of “Buy” and an average price target of $37.44.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Friday. The stock has a market capitalization of $81.69 billion, a price-to-earnings ratio of 36.90 and a beta of 0.75. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04. The stock’s 50 day moving average is $33.23 and its 200-day moving average is $30.79.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/astrazeneca-plc-azn-receives-hold-rating-from-shore-capital.html
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.07. The company had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. Astrazeneca PLC’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.21 EPS. On average, analysts expect that Astrazeneca PLC will post $2.97 earnings per share for the current year.
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is 78.29%.
A number of large investors have recently added to or reduced their stakes in the stock. Forester Capital Management LTD boosted its stake in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares during the period. First Interstate Bank boosted its stake in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock valued at $118,000 after buying an additional 2,730 shares during the period. Synovus Financial Corp boosted its stake in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock valued at $132,000 after buying an additional 1,000 shares during the period. Fifth Third Bancorp boosted its stake in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock valued at $140,000 after buying an additional 103 shares during the period. Finally, Integrated Investment Consultants LLC boosted its stake in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the period. 11.39% of the stock is owned by institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.